Indivior PLC (INDV.L)
18 Dec 2018
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|Executive Chairman of the Board|
|Chief Executive Officer, Executive Director|
|2017||Chief Financial Officer, Executive Director|
|Chief Human Resource Officer|
|2017||Chief Information and Innovation Officer|
- Indivior plans cheaper opioid addiction drug to keep copycats at bay
- UPDATE 2-Indivior plans cheaper opioid addiction drug to keep copycats at bay
- Indivior to launch cheaper opioid addiction drug; maintains forecast
- Oil slide and growth worries weigh FTSE 100 while mid-caps bounce
- UPDATE 1-Oil slide and growth worries weigh FTSE 100 while mid-caps bounce
- 3 hot shares to buy after today's gains?
- 3 shares to buy after today's half-time results?
- Will Indivior plc (+71%), Serco Group plc (+33%) & Indus Gas Limited (+105%) be among 2016's big winners?
- Are GlaxoSmithKline plc, Indivior plc and Alliance Pharma plc buys ahead of a potential Brexit?
- Can last week's winners Fresnillo plc (+10%), Indivior plc (+37%) and Supergroup plc (+7%) keep charging?
- Are GlaxoSmithKline plc and Indivior plc the perfect pharma pairing?